The proposed research aims to produce a highly potent and broadly neutralizing cocktail of """"""""evolved"""""""" human monoclonal antibodies for clinical evaluation in HIV-1 infections. Passive immunization is proposed for the treatment of individuals accidentally infected perhaps due to occupational exposure and in the treatment of infected mothers to reduce transmission rates and severity of disease in the infant. Treatment of long-term infected individuals with a cocktail of antibodies could be of value to reduce viral load in combination with other anti-retroviral agents. In vitro approaches will be developed using the phage display approach to evolve antibodies with the affinity and specificity required for this application. In preliminary experiments we have improved the affinity of an HIV-1 neutralizing antibody 100-fold to a final affinity of 10(-11)M. Neutralization of both laboratory and primary clinical isolates was improved. Human antibodies directed against the CD4-binding site and the V3 loop of the envelope glycoprotein gp120 and a conserved epitope on gp41 will be evolved to exceptional affinity and neutralizing ability. Antibodies will be characterized with respect to sequence, affinity for antigen, epitope recognized, and neutralizing ability as assessed with laboratory and primary clinical isolates of HIV-1. The properties of evolved antibodies will be far superior to those obtained by any other means and provide the best opportunity for testing passive immunotherapy in HIV-1 infection. The methods developed will be of general applicability to the modification of the specificity and affinity of any antibody. Mimetopes will be selected from constrained peptide libraries to bind optimized antibodies to explore their use as templates in the design of an HlV-1 vaccine. Mice will be immunized with mimetopes and the polyclonal response will be characterized as described for monoclonal antibodies. Crystallographic studies of evolved antibodies in complex with mimetopes or gp120, coupled with detailed characterization of the binding kinetics of these antibodies should accelerate the understanding of macromolecular recognition involving antibody/antigen interactions. Furthermore the solved ligand structures have potential as templates for vaccine design and inhibitors of HIV-1 infection. The generation of antibodies with exceptional affinities and specificities should both increase biological potency and decrease the cost of antibodies as therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI037470-03
Application #
2004216
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1994-12-01
Project End
1997-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Popkov, Mikhail; Mage, Rose G; Alexander, Cornelius B et al. (2003) Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 325:325-35
Berry, Jody D; Licea, Alexei; Popkov, Mikhail et al. (2003) Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid Hybridomics 22:23-31
Berry, Jody D; Rutherford, John; Silverman, Gregg J et al. (2003) Development of functional human monoclonal single-chain variable fragment antibody against HIV-1 from human cervical B cells. Hybrid Hybridomics 22:97-108
Goncalves, Joao; Silva, Frederico; Freitas-Vieira, Acilino et al. (2002) Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. J Biol Chem 277:32036-45
Shabat, D; Lode, H N; Pertl, U et al. (2001) In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc Natl Acad Sci U S A 98:7528-33
Andris-Widhopf, J; Rader, C; Steinberger, P et al. (2000) Methods for the generation of chicken monoclonal antibody fragments by phage display. J Immunol Methods 242:159-81
Bera, T K; Kennedy, P E; Berger, E A et al. (1998) Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med 4:384-91
Zwick, M B; Bonnycastle, L L; Noren, K A et al. (1998) The maltose-binding protein as a scaffold for monovalent display of peptides derived from phage libraries. Anal Biochem 264:87-97
Rader, C; Cheresh, D A; Barbas 3rd, C F (1998) A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci U S A 95:8910-5
Gauduin, M C; Parren, P W; Weir, R et al. (1997) Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 3:1389-93

Showing the most recent 10 out of 13 publications